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Abstract 
Objective 
Kawasaki disease (KD) is a vasculitis that mostly occurs in young children and rarely in 
adults. We analyzed the characteristics of adult-onset KD (AKD) in France.  
Methods 
We collected retrospective and prospective data for patients with a diagnosis of KD occurring 
after the age of 18 years. Cases were obtained via various French medical networks and 
identified from the international literature.  
Results 
We included 43 patients of AKD at 26 institution from 1992 to 2015, with mean (SD) age 30 
(11) years (range 18–68) and sex ratio (M/F) 1.2; 34 patients met the American Heart 
Association criteria and 9 were incomplete AKD. The median time to diagnosis was 13 days 
(interquartile range 8–21). The main symptoms were fever (100%), exanthema (98%), 
changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical 
adenitis (55%) and cardiac abnormalities (45%). Overall, 35% of patients showed large-vessel 
vasculitis: coronary vasculitis (26%) and coronary aneurysm (19%). Treatment was mostly 
intravenous immunoglobulins (79%) and aspirin (81%). Four patients showed myocardial 
infarction due to coronary vasculitis, but none were treated with IVIg because of late 
diagnosis. After a median follow-up of 5 months (range 1–117), persistent aneurysm was 
noted in 9% of cases. Damage was significantly lower with early treatment than late or no 
treatment (p=0.01). 
Conclusion 
Given the high frequency of cardiac involvement and complications in this series of AKD, 
diagnosis and treatment should not be delayed, and early IVIg treatment seems to improve the 
outcome. 
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Introduction 
Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute 
necrotizing vasculitis of the medium and small-sized arteries with severity related to coronary 
aneurysm[1]. First described in Japan in 1967[2], KD occurs in both endemic and community-
wide epidemic forms in children of all races[3,4]. A genetic susceptibility has been identified 
by genome-wide association study (GWAS), but to date, the pathophysiology remains 
unclear[5].  
Adult-onset KD (AKD) is rare and often misdiagnosed. A recent review including 
post-infectious cases described 100 cases of AKD[6]. Most reports were of 1 or 2 cases, and 
data were often missing, especially for infectious disease investigations as a differential 
diagnosis, detection of coronary abnormalities and long-term outcome. Although AKD is rare, 
it can be devastating, and many questions remain regarding its optimal management, 
especially treatment with intravenous immunoglobulin (IVIg) with late diagnosis.  
To improve our knowledge and management of AKD, we report a series of AKD from 
France. 
Methods:  
First, we searched for case reports of AKD in France that were published in English and/or 
French from 1967 (when KD was first described) through July 2015 in MEDLINE via 
PubMed and the National Library of Medicine. Then we contacted the authors of the reports 
for approval to include the cases in this report. Furthermore, we searched for other cases in 
the French Vasculitis Study Group (FVSG) database and in posters presented at the French 
Society of Internal Medicine (SNFMI) meetings. The aim of this study was presented at the 
annual meeting of Internal Medicine, Dermatology and Rheumatology in December 2014. We 
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placed a call for cases on the website of the French Club Rhumatismes et Inflammation 
(www.cri-net.com/recherche/index.asp) and on the French KD registry “Kawanet”. 
We included cases that fulfilled the international diagnosis criteria for KD[7]. A 
complete diagnosis is defined by the presence of unexplained fever >5 days and 4 of the 5 
main clinical features: 1) extremity changes starting with edema or erythema progressing to 
desquamation of feet and hands 2) polymorphous exanthema, 3) bilateral conjunctivitis 
without exudates, 4) oral changes including injected pharynx or lips, and 5) cervical 
lymphadenopathy >1.5 cm. Incomplete KD is defined by 3 of the above 5 criteria and 
coronary artery disease. To be included in this AKD series, patient had to have onset of 
manifestations after the age of 18 years.  
We excluded cases with 1) drug hypersensitivity, staphylococcal scalded skin 
syndrome, infectious disease, inflammatory and autoimmune disease that could explain all or 
some of the clinical manifestations[8]; 2) unknown HIV serology status; 3) onset of some 
clinical findings before age 18; and 4) incomplete cases without coronary artery disease. 
Participating physicians systematically collected data on 1) gender, date of birth, date 
of diagnosis, co-morbidities and cardiovascular risk factors; 2) disease phenotype, including 
clinical, laboratory and cardiovascular findings; 3) treatment, including dates of initiation and 
discontinuation, concomitant treatment and adverse effects; and 4) outcome including clinical 
and cardiovascular features. Vasculitis Damage Index (VDI)[9] and Birmingham Vasculitis 
Activity Score (BVAS)[10] at diagnosis and at latest news were retrospectively determined 
and analyzed. 
Coronary vasculitis was defined by at least one of the following features: CT and CT 
angiography findings of concentric mural thickening of the artery wall and in the venous 
phase, presence of a “double ring” enhancement pattern[11]; ultrasonography or 
echocardiography findings of a hyperechogenic artery wall[7,11]; and MRI findings of 
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thickened artery wall in T1 or T2 echo-spin images and presence of wall edema in short tau 
inversion recovery images[11]. Aneurysm was defined by an increase in artery caliber as 
compared with adjacent segments and loss of parallelism of the artery wall[11]. Early 
treatment was defined by IVIG infusion before day 9 after AKD onset and late treatment was 
defined by IVIG infusion after day 10 of onset. We compared early treatment and late or no 
treatment. 
Statistical analysis 
The Fisher exact test was used for comparing qualitative data and the Wilcoxon test for 
quantitative data by use of R 3.2.1 (2015) with the Package Rcmdr 2.1.7 (2007). P<0.05 was 
considered statistically significant.  
This study was approved by Institutional research board Ile de France VII and National 
Council of Information and Freedoms. 
Results 
We collected 56 patients of AKD; 13 were excluded because of unknown HIV serology 
(n=5)[12–16]; presence of ankylosing spondylitis associated with an atypical evolution 
(n=1)[17]; recurrent palmo plantar psoriasis (n=1); KD case associated with Chikungunya 
infection (n=1) or Streptococcus infection (n=1); incomplete cases without coronary artery 
disease (n=2) and unknown age of onset (n=1) or age< 18 years (n=1). Within the remaining 
43 AKD patients, 28 (65%) were reported in the literature[18–33]. AKD diagnosis was 
complete for 79% of patients (n=34) and incomplete for 21% (n=9) (Table 1). The cases were 
diagnosed between 1992 and 2015 in 26 different French centers (Figure 1). Internal medicine 
departments were the most represented (58% of cases); 21% of cases were diagnosed by 
cardiologists, 12% by dermatologists, 7% by infectious diseases specialists and 2% in 
intensive care unit. 
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The mean (SD) age at diagnosis was 31 (11) years (range 18-68). The male to female 
ratio was 1.2. All patients were living in France but had various ethnic backgrounds: 26/43 
were Caucasian (60%), 7 were from Africa (16%), 2 were from the Caribbean (5%), 1 was 
from Asia (2%) and 1 was from the Middle East (2%); data were not available for 6 (14%). 
None of the patients had a pediatric medical history of KD. Thirteen (30%) had at least 
one cardiovascular risk factor at the time of AKD diagnosis: active smoking (26%; median 
pack-years 11 [range 1-25]), history of smoking (7%), hypercholesterolemia (9%), 
hypertension (7%) and type II diabetes mellitus (7%). Two patients had had cardiovascular 
disease: one smoker patient with high blood pressure had had myocardial infarction (MI, 
patient 23) and one had had idiopathic pericarditis 10 years before AKD diagnosis (patient 
22). Other notable medical histories included IgA vasculitis (patient 8), asthma (patient 15) 
and erythema multiform (patient 29).  
 
Clinical characteristics (Table 2) 
The median time from AKD to diagnosis was 13 days (IQR 8-21; range 0-3280). Fourty-
seven % of the cases (n=20) showed a seasonal peak in disease onset between October and 
February (Figure 2). AKD clinical manifestations included fever (100%) that lasted a median 
of 13 days (IQR 10-18; range 4-64), changes in the extremities (91%) with peeling (77%) 
after a median delay of 13 days (IQR 11-17; range 2-45), hands and feet edema (61%) and 
extremity rash (74%). Apart from extremity rash, diffuse exanthema was present in 98% of 
cases and described in 81%: measles-like (47%), scarlatiniform (16%), polymorphous (9%), 
transient (7%) and rubella-like (2%). Patients also showed oral mucosa and lip changes (91%) 
with oropharyngeal injection (61%), dry fissured lips (72%), strawberry tongue (47%); 
bilateral non-exudative conjunctivitis (81%) and cervical lymphadenopathy (56%). Cardiac 
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manifestations were reported in 44% of cases: chest pain (23%), cardiogenic shock (5%), left 
(9%) and right heart failure (5%). The mean (SD) initial BVAS was 8 (4) (range 3-18). 
On admission, median C-reactive protein level was 205 mg/L (IQR 104-298; range 
54-540) and first-hour erythrocyte sedimentation rate was 70 mm (IQR 48-90; range 4-112). 
Other biological abnormalities are in Table 3. 
 
Cardiovascular findings at diagnosis 
Cardiac involvement was screened in all patients by echocardiography (93%), coronary CT 
angiography (33%), coronary angiography (19%), stress test (16%) and cardiac MRI (7%). In 
total, 19 patients (44%) had echocardiography only without further investigations; 3 patients 
(7%) also underwent extracoronary angiography. 
Initial echocardiography was abnormal for 19 patients cases (44%) and revealed 
pericarditis (26%), myocarditis (14%) associated with pericarditis (7%), hyperechogenic 
coronary arteries (14%), coronary aneurysm (5%), systolic dysfunction (16%), hypokinesia 
(16%), akinesia (7%), valvulopathy (2.5%) and intracavity thrombosis (2.5%).  
Overall, 35% of patients showed evidence of large-vessel vasculitis (LVV), including 
coronary and extra-coronary arteries; 11 (26%) presented evidence of coronary vasculitis and 
8 (19%) evidence of coronary aneurysm by coronary angiography (63%), coronary CT 
angiography (25%) or echocardiography (13%). Eleven patients showed coronary vasculitis 
on 20 locations: left anterior descending (n=7), left main coronary (n=4), right coronary (n=3), 
circumflex (n=3) and diagonal branch (n=3). Eight patients showed coronary aneurysms on 
15 locations: right coronary (n=5), left anterior descending (n=4), left main coronary (n=4), 
circumflex (n=1) and diagonal branch (n=1). 
In all, 4 cases (9%) featured MI, none treated with intravenous immunoglobulin (IVIg), 
because of diagnosis delay after the MI onset; all had documented evidence of coronary 
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aneurysm (patients 1, 7, 10 and 20). Atherosclerosis (2%) was found in one 52-year-old active 
smoker (20 pack-years) receiving treatment for type II diabetes mellitus and 
hypercholesterolemia. This patient also presented evidence of coronary vasculitis on coronary 
CT angiography. 
Two cases (5%) featured peripheral vasculitis: a 22-year-old male who presented right 
brachial aneurysm and coronary aneurysm, spleen artery vasculitis and bilateral occlusion of 
lower-limb distal arteries complicated by acute lower-limb ischemia[26]; and a 29-year-old 
female who presented gastroduodenal and splenic artery vasculitis complicated by spleen 
infarcts without coronary aneurysm[20].  
Presence of at least one cardiovascular risk factor was not significantly associated with 
LVV (50% of cases with LVV vs 25% without, p=0.16). The proportion of cases with 
echocardiography as the sole investigation without further cardiac check-up did not differ by 
presence or absence of LVV (33% with LVV vs 50% without, p=0.35). 
 
Treatment and disease course (Table 4) 
In total, 34cases (79%) received IVIg at a median of 11 days (IQR 9-18; range 1-69) after the 
beginning of the disease; 12 (28%) had early treatment. Most (91%) received a single course 
of IVIg, 6% received 2 courses and 3% received 4. The infusion dose was 2 g/kg for 94% of 
patients, and 1.6 g/kg for 6%. Duration of IVIg was 1 day (17%), 2 days (45%), 3 days (7%), 
4 days (3%) and 5 days (28%). Fever disappeared after a median of 2 days (range 0-4) for 
91% of patients. Apyrexia delay after IVIg seems longer with early treatment versus late 
treatment: 2 days (IQR 2-3, range 1-4) versus 1.5 (IQR 1-2, range 0-4) (p=0.07) (Table 4). 
Patients with early IVIg treatment versus late or no treatment did not differ in 
frequency of LVV (33% vs 35%, p=1) but did differ in fever duration: median 10 days (IQR 
8-11; range 4-12) versus 16 (IQR 11-21; range 5-64) (p=0.002) (Table 4). The initial BVAS 
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was significantly lower in the early than late or no treatment group: median 4 (IQR 3-6.5; 
range 3-13) versus 9 (IQR 5-11; range 3-18) in late or no treatment group (p=0.006) (Table 4). 
Most patients (86%) received aspirin: 24 (56%) had an anti-inflammatory dose and 24 
(56%) an anti-aggregant dose; 23 (53%) received IVIg plus aspirin at an anti-inflammatory 
dose. In the early-treated group, 83% of patients received aspirin at an anti-inflammatory dose 
versus 45% in the late or untreated group (p=0.04). The other anti-inflammatory drugs used 
were steroids (14%), non-steroidal anti-inflammatory drugs (7%) and colchicine (5%). The 
use of cardiovascular drugs was reported for 28% of patients and included curative 
anticoagulation (12%) (without reported hemorrhage), angiotensin-converting enzyme 
inhibitors (16%), beta-blockers (12%), spironolactone (5%) and amiodarone (2%). 
The median duration of follow-up after diagnosis was 5 months (IQR 2-19; range 1-
117) and seems higher for patients with than without LVV: median 11 months (IQR 4-22; 
range 1-117) versus 4 (IQR 2-13; range 1-78) (p=0.14). After 6 months, the proportion of 
coronary aneurysm detected by cardiac imaging decreased from 19% to 14% and to 9% at the 
end of the follow-up. The median BVAS decreased to 0 (range 0-6) at the end of follow-up.  
Late complications included bilateral lower-limb ischemia with gangrene requiring a 
trans–metacarpal-level amputation in 1 patient (2%) and heart failure at the end of follow-up 
in 2 patients (5%). The median VDI was 0 (IQR 0-1, range 0-6). The VDI was significantly 
lower with early than late or no treatment: median 0 (range 0-1) versus 0 (range 0-6) for cases 
with late or no treatment (p=0.01) (Table 4). No death was reported but one untreated patient 
relapsed after 1 month (patient 25).  
Discussion 
We report here the largest series of patients with adult-onset KD. These patients had a high 
frequency of cardiac involvement and complications, and MI and damage may be less 
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frequent with early IVIg treatment than late or no treatment. These results seem similar to 
those found for childhood KD (CKD)[7]. 
 The BVAS and VDI are commonly used in adult vasculitis monitoring. In children, 
these scores are modified as the Pediatric Vasculitis Activity Score (PVAS)[34] and Pediatric 
VDI (PVDI)[35], respectively, but are not yet used in KD. 
Our literature search of AKD found 25 infections mimicking KD: post-HIV infection 
(n=20)[36–49], Epstein-Barr virus infection (n=1)[50], Streptococcus infection (n=2)[51], 
Coxiella infection (n=1)[52] and Chikungunya infection (n=1). In our literature analysis, we 
did not include complications of known or suspected KD in childhood, infectious cases 
(n=25) and inaccessible cases (n=10)[53–62]. 
The total reported cases of AKD in the PubMed database represents 41 non-French 
complete cases[6,8,63–101] and 5 incomplete cases[102–106]. Some reports published 
between 1976 and 1996 were inaccessible (n=10)[53–62]. Including non-French cases (n=46), 
our observations (n=43), 89 observations of non-HIV AKD have been reported since 1979.  
The American Heart Association diagnostic criteria seem applicable for AKD, with 
the complete form being the most frequent. Most of the incomplete cases were diagnosed by 
the presence of coronary vasculitis. A few cases were retrospectively diagnosed after MI 
complicating coronary aneurysm[26,33], as observed in this series.  
AKD clinical signs appeared comparable to those for CKD, but the frequency of 
clinical signs could differ between the 2 groups. In the pediatric study of Saundankar et al., in 
2014[107], the frequency of signs we found were similar to that cited for adult polymorphous 
exanthema (98% vs 96%). Coronary aneurysm in our adult patients with late or no treatment 
seemed as prevalent as in children (19% vs 15-25%[7,108]). Some symptoms less common 
for adults than children included oropharynx changes (91% vs 96%). lymphadenopathy (56% 
vs 63%), conjunctivitis (81% vs 89%) and gastrointestinal symptoms (56% vs 60%), whereas 
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symptoms more common for adults than children were changes in extremities (91% vs 76%) 
and arthritis (42% vs 28%). AKD disease appears to share other features with CKD such as 
pericarditis, myocarditis, cardiac shock and neurological manifestations such as aseptic 
meningitis5. In addition, adult biological findings were similar to those found in children, with 
a marked increase in acute-phase reactants, delayed thrombocytosis, hyponatremia, hepatic 
cytolysis and aseptic leukocyturia[7]. We found 16% hypereosinophilia in our adult cases 
with 36% reported in CKD[109,110]. In the extra-tropical latitudes of the northern 
hemisphere, a winter peak in CKD has been long observed[111]. To our knowledge, this is 
the first time the same seasonal pattern has been highlighted in AKD. 
Given the exceptional nature and the need to rule out many differential diagnoses, the 
diagnosis of AKD is late and probably underdiagnosed. The differential diagnosis of AKD 
include: drug hypersensitivity reactions, toxic shock syndrome, erythema multiforme, scarlet 
fever, measles, rubella, parvovirus, infectious mononucleosis, hand-foot-and-mouth syndrome, 
leptospirosis, rocky mountain and Mediterranean spotted fever, syphilis, endocarditis, 
rheumatic fever, Reiter syndrome, palmoplantar psoriasis, Behçet disease, polyarteritis nodosa, 
Bazex syndrome, etc[8,33]. Hence, the diagnostic delay is longer for AKD than CKD, for 
which it is usually <7 days[7]. In addition, physicians must consider cardiovascular risk 
factors during the acute phase of AKD to avoid further cardiovascular complications due to 
the development of atherosclerosis[112]. 
 In general, AKD is less treated than CKD[113]. IVIg was given for only 79% of our 
adult cases and was combined with aspirin at an anti-inflammatory dose for 53%. 
Undertreatment of AKD can be explained by the natural history of the disease, which can 
vanish spontaneously without treatment, and by the absence of treatment standardization in 
cases diagnosed after 10 days of fever. However, even when administered late, IVIg seemed 
effective to control fever in 91% of patients, but vasculitis is not 100% preventable. For 21% 
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of cases, late diagnosis and the absence of a gold standard treatment was associated with a 
higher coronary aneurysm rate as compared with well-treated CKD[7]. Of note, the initial 
cardiac event rate was high, with 44% cardiac impairment and 44% abnormal 
echocardiography findings. The presence of extracoronary vasculitis in CKD is rarely 
described[114], as compared with 5% of our AKD cases. 
Given the severity of coronary aneurysm, all patients, especially those with cardiac 
manifestations, should be screened for coronary vasculitis. Most of our cases of incident 
coronary aneurysm (86%) were diagnosed by coronary angiography or coronary CT 
angiography. Considering the limitations of echocardiography to entirely view coronary 
arteries in adults, this screening should include, in addition to echocardiography, coronary 
angiography, coronary CT angiography and/or cardiac MRI[115]. However, coronary 
angiography is not the best morphological exam for coronary injury screening. Coronary 
angiography detects later and more severe injuries such as stenosis, aneurysm and thrombosis. 
It does not seem able to detect early wall-artery injuries that are more easily seen by coronary 
CT angiography[116] or echocardiography[117].  
Although the pathophysiology of KD is becoming better understood, specifically the 
genetics mechanism[118], it still remains unclear. Recently, GWAS revealed an association of 
many genes: the ITPKC gene implicated in negative regulation of T cells via an NFAT 
pathway[119] and the FcRg2a gene associated with susceptibility to KD and also linked to 
IVIg response[120]. Genetic polymorphism might explain why the risk of KD could be 
delayed in adults. There is also a better understanding of the inflammation process: HMGB1 
could get involved in KD by amplifying the inflammation[121]. 
Although original, our study remains limited by its retrospective design, which 
prevented an exhaustive collection of data, and by a probable selection bias toward the most 
severe cases. Indeed, cardiovascular manifestations may be the symptom suggesting a 
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diagnosis of KD among adult physicians, and lead to a possible overestimation of this 
complication in this age group.  
Conclusion 
KD remains an exceptional disease in adulthood, but all cases may not have been diagnosed 
and are probably underreported. The high rate of cardiac complications might be related to 
both a long diagnosis delay and absence of IVIg treatment. An increased awareness of adult 
KD is warranted in the medical community, because AKD carries a serious prognosis in the 
short and long term, with irreversible damage in the absence of prompt management.  
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Figure 1: Number of adult KD diagnoses by year  
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Table 2: Clinical findings for 43 patients with adult KD 
 
Clinical signs No. of cases (%) 
General signs 
            Fever 
            Lymphadenopathy 
43 (100) 
43 (100) 
24 (56) 
Mucocutaneous signs 
            Extremities changes 
            Edema 
            Peeling 
            Diffuse exanthema 
            Oral cavity changes 
            Cheilitis 
            Strawberry tongue 
            Injected oral mucosa 
43 (100) 
39 (91) 
26 (61) 
33 (77) 
42 (98) 
39 (91) 
31 (72) 
20 (47) 
26 (61) 
Ocular involvement 
            Conjunctivitis 
            Anterior uveitis  
            Posterior uveitis  
            Scleritis 
35 (81) 
35 (81) 
3 (7) 
1 (2) 
3 (7) 
Cardiac signs 
            Chest pain 
            Cardiac shock 
            Left heart failure 
            Right heart failure 
            Myocardial infarction 
19 (44) 
10 (23) 
2 (5) 
4 (9) 
2 (5) 
4 (9) 
Rheumatologic involvement 
            Joint pain 
            Myalgia 
22 (51) 
18 (42) 
14 (33) 
Gastrointestinal involvement 
            Abdominal pain 
            Diarrhea 
            Jaundice 
            Emesis 
            Hepatomegaly 
            Splenomegaly 
24 (56) 
11 (26) 
5 (12) 
10 (23) 
6 (14) 
6 (14) 
5 (12) 
Neurological involvement 
            Headache 
            Confusion 
            Aseptic meningitis 
            Hearing loss 
            Dizziness 
10 (23) 
11 (26) 
2 (5) 
3 (7) 
2 (5) 
2 (5) 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
Table 3: Biological findings for 43 patients with adult KD 
 
Hematology Platelets (n=33): 358 g/L (210-656), 
WBC (n=38): 15 G/L (9.3-20.8),  
Neutrophils (n=32): 14 g/L (9.7-18), 
Eosinophils (n=14) 0.7 g/L (0.3-1.6), hypereosinophilia (n=7)  
Hemoglobin (n=23): 12 g/dL (11.2-13.6). 
 
Biochemistry 
  
CRP (n=38): 205 mg/L (104-298),  
ESR (n=19): 70 mm (48-90).  
Fibrinogen (n=19): 7.9 g/L (6.1-10.3) 
Ferritin (n=10): 840 μg/L (240-1327) 
Procalcitonin (n=10): 1.4 μg/L (0.04-6.4)  
SGOT (n=33): 71 IU/L (45-130), 
SGPT (n=34): 109 IU/L (58-185), hepatic cytolysis (n=23) 
Total bilirubin (n=20): 30 μg/L (IQ 17-69), elevation (n=10) 
Troponin (n=18): 0.47 ng/mL (0.26-0.8), elevation (n=9) 
Natremia (n=19): 133 mmol/L (130-137), hyponatremia (n=9) 
Creatininemia (n=18): 67 μmol/L (60-84) 
Albuminemia (n=12): 28 g/L (22-32) 
 
Infectiology 
 
Blood culture (n=43) sterile (100%)  
Urine culture (n=43) sterile (100%), leucocyturia (n=8). 
Lumbar puncture (n=11): sterile CSF (100%), CSF pleiocytosis (18%) 
elevated CSF protein (27%).  
Serology: HIV (n=43): negative (100%), hepatitis B (n=31) negative 
(100%), hepatitis C (n=30): negative (100%), CMV (n=27): negative 
(100%), EBV (n=25): negative (100%), parvovirus B19 (n=22): negative 
(100%), measles (n=7): negative (100%), 
Mycoplasma pneumoniae (n=5): negative (100%), Rickettsia conorii 
(n=18): negative (100%), streptococcal antigens (n=14): negative (100%), 
Leptospirosis (n=15): negative (100%), syphilis (n=14): negative (100%), 
Coxiella (n=7): negative (100%), Brucella (n=6): negative (100%), 
Borrelia (n=3): negative (100%), Toxoplasma (n=9): negative (100%). 
 
 Immunology Anti-nuclear antibodies (n=24): negative (100%) 
Anti-DNA antibodies (n=17): negative (100%), 
Nuclear specificity (n=16): negative (100%), 
Anti-neutrophil cytoplasmic antibodies (n=20): negative (100%) 
Circulating anticoagulant (n=5): negative (100%) 
Anti-B2GP1 antibodies (n=5): negative (100%) 
Anticardiolipin antibodies (n=6): positive (16%), negative (84%) 
Cryoglobulin (n=8): negative (100%) 
 
Data are no. of available results: median (interquartile range)  
WBC: white blood cells, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, 
SGOT: serum glutamate-oxaloacetate transaminase, SGPT: serum glutamic-pyruvic 
transaminase, CMV: cytomegalovirus, EBV: Epstein-Barr virus 
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Table 4: Early treatment (before day 9 after presentation) versus late 
or no treatment in 43 patients with KD 
 
Characteristics Early treatment  (n=12) 
Late or no treatment  
(n=31) P value 
Age (years), median (range) 28 (18-50) 27 (18-68) 0.98 
M/F ratio 1 1.2 1 
Smoking 3/12 (25) 8/31 (26) 1 
Cardiovascular disease risk factor  3/12 (25) 10/31 (32) 0.72 
Fever duration (days), median (range) 10 (4-12) 16 (5-64) 0.002* 
Peeling delay (days), median (range) 11 (2-27) 15 (4-45) 0.07 
Apyrexia delay after IVIg (days),  
median (range) 2 (1-4) 1.5 (0-4) 0.07 
Cardiac screening limited to 
echocardiography 8/12 (67) 11/31 (35) 0.09 
Initial abnormal echocardiography 8/12 (67) 16/31 (52) 0.50 
Myocardial infarction 0/12 (0) 4/31 (13) 0.56 
Pericarditis 3/12 (25) 8/31 (26) 1 
Myocarditis 1/12 (8) 5/31 (16) 0.65 
Large-vessel vasculitis 4/12 (33) 11/31 (35) 1 
Coronary aneurysm 1/12 (8) 7/31 (23) 0.40 
Coronary vasculitis 4/12 (33) 7/31 (23) 0.47 
Anti-inflammatory dose of aspirin 10/12 (83) 14/31 (45) 0.04* 
Initial BVAS, median (range) 4 (3-13) 9 (3-18) 0.006* 
VDI, median (range) 0 (0-1) 0 (0-6) 0.01* 
Follow-up (months), median (range) 5 (1-110) 5 (1-117) 0.87 
 
Data are no. (%) unless indicated. 
IVIg: intravenous immunoglobulins, BVAS: Birmingham Vasculitis Activity Score, VDI: 
Vasculitis Damage Index 
